TABLE 2.

Primers used in this study

Name	Description	Sequence
P1	Pg0791 (vimE) forward	5′ATGAATACTGAAGTAATCCAC 3′
P2	Pg0791 (vimE) reverse	5′ TTGGTCGATGGCCGTTTCGTA 3′
P3	Pg0791 (vimE) reverse (intragenic)	5′ TCAGCACTTCCTTGCACAAC 3′
P4	Pg0792 forward (intragenic)	5′ CAGTCGCACGGCGATGTGTTT 3′
P5	Pg0792 reverse (intragenic)	5′ GCAGGATGGAGCGGGAGTATTC 3′
P6	Pg0792 reverse	5′ TTCACGCGAAAAAGTGGAGAT 3′
P7	vimA forward	5′ ATGCCCATCCCTCTATACCTG 3′
P8	vimA reverse	5′ TACCTGTTTTTGCTGACCGG 3′
P9	recA forward	5′ ATGGCAGAAGAAAAGATACCC 3′
P10	recA reverse	5′ TGAATGTTTGTTGCGAATGG 3′
P11	pro-kgp forward	5′ ATGAGGAAATTATTATTGCTGATCG 3′
P12	pro-kgp reverse	5′ TTGAAGAGCTGTTTATAAGCTGTTT 3′
P13	pro-rgpA forward	5′ ATGAAAAACTTGAACAAGTTTGTTTC 3′
P14	pro-rgpA reverse	5′ CCGGTGTGTAACGCCCTG 3′
P15	pro-rgpB forward	5′ CGACCGATGAAGACTTCG 3′
P16	pro-rgpB reverse	5′ TGAAGACGCTCTTATAGATATCTT 3′
P17	erythromycin forward	5′ TATTAGGCCTATAGCTTCCGCTATT 3′
P18	erythromycin reverse	5′ AATAGGCCTTAGTAACGTGTAACTTT 3′